Mucinex Children's Liquid - FreeFrom Multi-Symptom Cold & Flu Nighttime 4oz
- MULTI-SYMPTOM COLD & FLU RELIEF: Mucinex Children’s FreeFrom Multi-Symptom Cold & Flu Nighttime helps relieve common cold and flu symptoms: cough, sore throat, stuffy & runny nose, reduces fever, sneezing, nasal congestion, headache and minor aches and pains
- FREE FROM UNWANTED ADDITIVES: Free from unwanted additives such as artificial flavors, colors, dyes; No alcohol and sugar
- #1 PEDIATRICIAN RECOMMENDED: Mucinex Children’s is the #1 Pediatrician Recommended Brand among Non-Homeopathic Children’s Cough / Cold OTC products
- PAIN RELIEVER & FEVER REDUCER: Contains Acetaminophen which relieves pain, reduces fever and help relieve your sore throat symptoms
- COUGH SUPPRESSANT: Contains Dextromethorphan HBr that helps relieve cough
- NASAL DECONGESTANT: Contains Phenylephrine HCl that provides relief for nasal congestion, sinus congestion and pressure
- ANTIHISTAMINE: Contains Triprolidine HCl that alleviates sneezing, runny nose, itching of the nose and watery eyes
Description:
Mucinex Children’s FreeFrom Multi-Symptom Cold & Flu Nighttime helps relieve common cold and flu symptoms: cough, sore throat, stuffy & runny nose, sneezing, nasal congestion, headache and minor aches & pains. It also reduces fever. The product is free from unwanted additives such as artificial flavors, colors or dyes, alcohol and sugar. Mucinex Children’s is the #1 Pediatrician Recommended Brand*. It is available in Elderberry & Cherry Natural flavor. It is to be used for Children 6 years and over. Mucinex FreeFrom range is also available for Adults. KEY SYMPTOMS RELIEVED: Cough, Sore Throat, Stuffy Nose, Runny Nose, Sneezing, Nasal Congestion, Headache, minor aches and pains. The product also reduces fever. ACTIVE INGREDIENTS: Acetaminophen – Pain reliever/fever reducer, Dextromethorphan HBr – Cough suppressant, Phenylephrine HCI – Nasal decongestant, Triprolidine HCI – Antihistamine Use as directed *among Non-Homeopathic Children’s Cough / Cold OTC products (IQVIA, ProVoice Survey, January 2022)